SAN DIEGO, June 20, 2018 – ProSciento Inc., a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, today announced a collaboration with Tidepool, a nonprofit software and mobile app developer for diabetes data management, to integrate Tidepool’s HIPAA-compliant data aggregation platform into clinical trials that utilize multiple diabetes devices.
Tidepool’s Clinical Study Platform is a secure, cloud-based application that captures and consolidates data from continuous glucose monitors (CGM), insulin pumps and blood glucose meters. The platform will allow ProSciento to monitor and analyze data from multiple devices concurrently and instantaneously for inpatient and outpatient studies across all clinical trial sites.
“Perhaps the most exciting benefit of Tidepool’s platform for clinical trials is the quantity and value of the data being aggregated. Their secure, state-of-the-art software platform transforms the data capture and management cycle of clinical trials when employing multiple devices and can optimize data accessibility, management and analysis,” said Marcus Hompesch, MD, ProSciento’s Chief Executive Officer.
“We’re excited to be partnering with ProSciento, a CRO with extensive experience in diabetes clinical trials. Working with ProSciento provides us an opportunity to expand the use of our platform across a global clinical trial site network, while enabling 24/7 secure access and multiple device data monitoring to support ProSciento’s clinical trials for sponsors developing new therapeutics for diabetes patients worldwide,” said Howard Look, Tidepool’s founder, CEO and President.
About Tidepool, Inc.
Tidepool is a 501(c)(3) nonprofit organization providing software to collect, manage, store and gain insights from insulin pump, continuous glucose monitor, blood glucose meter, and ketone meter data. The company provides diabetes data management services to industry, in addition to free consumer software for people with diabetes and clinicians. Tidepool is registered with the FDA and complies with all applicable FDA regulations, including 21 CFR 820. Tidepool also complies with all HIPAA privacy, security and breach notification regulations and is GDPR compliant. For more information, please visit www.tidepool.org.
About ProSciento, Inc.
ProSciento is a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. The company is widely recognized for its scientific and therapeutic expertise, unparalleled experience in metabolism, and utilization of advanced, specialized methodologies for metabolic clinical research. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with a comprehensive and scalable portfolio of services, from strategic planning through completion of early phase clinical drug and device development. Founded in 2003, ProSciento has conducted more than 280 clinical projects for NASH, diabetes and obesity and supported the development of numerous metabolic drugs and devices on the market globally today. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 (858) 663-6148
abby.devine@prosciento.com
For business development inquires:
bd@prosciento.com
For clinical study enrollment inquiries:
Tel: +1 (866) 308-7427
volunteer@prosciento.com
